New blood test can detect cancers before symptoms appear
A new blood test, miONCO-Dx, is being evaluated for use in the NHS. It can detect a dozen cancers, including bowel cancer, before symptoms appear.
The UK government is backing the next testing phase, aiming to improve early detection and survival rates.
The research will be conducted at the newly named BowelBabe Laboratory at the Francis Crick Institute, in honor of Dame Deborah James.
The miONCO-Dx test analyses microRNA in blood samples, using AI to identify and locate cancers with 99 per cent accuracy in initial tests.
A £2.4 million grant will support a trial involving 8,000 patients to gather evidence for NHS approval.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
30 minutes ago
- Telegraph
Carrie Johnson taken to hospital with severe dehydration
Carrie Johnson was admitted to hospital with severe dehydration because of the hot weather. The wife of Boris Johnson said she had spent two nights in hospital after a 'brutal' week in which she also suffered from mastitis, a form of breast inflammation. Mrs Johnson gave birth to her fourth child, a girl named Poppy, in May. Writing on Instagram on Friday, she said: 'Being hospitalised for two nights for severe dehydration was not on my postpartum bingo card. 'Breastfeeding mums make sure you eat and drink enough in this heat. Especially if your babe is clusterfeeding.' Temperatures are set to surpass 30C this weekend. Clusterfeeding is when a baby feeds very frequently in a few hours before going without milk for extended periods. Mrs Johnson added: 'This week has honestly been brutal. Mastitis (me), Reflux (her), Dehydration (me). What a pair we are! But thank you for all the kindest messages, especially all the brilliant advice on reflux. Really appreciate it and made me feel way less alone going [through] it all. And as ever, thanks to our amazing NHS.' Mr and Mrs Johnson have three other children together: Wilf, five, Romy, three, and Frank, one. Mrs Johnson is a former communications officer who worked for the Conservative Party from 2009 to 2019. She acted as a media special adviser for Conservative Cabinet ministers including Sajid Javid and John Whittingdale. In 2018, at the age of 29, she was appointed as the Conservative party's head of communications during the government of Theresa May. She left the position a year later. Her relationship with Mr Johnson was announced in 2019 as he was preparing to run for the leadership of the Conservative Party and the country. When Mr Johnson became premier in July of that year, she became the first unmarried partner of a prime minister to reside in Downing Street. While living there, they had Wilfred and Romy. They are thought to have met as early as 2010 when Mrs Johnson, née Symonds, was a press officer working on Mr Johnson's campaign to be reselected as the Conservative candidate for London mayor. The couple now live in South Oxfordshire where they own a Grade II listed 17th-century country house. The house is surrounded by five acres of grounds and has nine bedrooms.
Telegraph
an hour ago
- Telegraph
NHS drug charges row hits deadlock
Ministers have failed to agree a crucial deal on NHS drug charges that was meant to be at the centre of a plan to boost growth. Talks on Friday between the Government and pharmaceutical industry bosses ended without an agreement on how much the NHS is able to claw back in rebates on drugs. Ministers had been hoping to be able to address industry complaints of unfairness prior to the publication a strategy for the sector, expected next week. One senior pharmaceutical executive said: 'If a [NHS clawback] deal is not secured, it's a missed opportunity for the life sciences sector plan and one which blocks the UK's ambition to be a life sciences superpower.' Another said that the UK needed to show it wanted to make the scheme competitive again, adding: 'Without that, all the high statements of ambition or new strategies in the world are not going to make the UK a leading life sciences centre.' The Department of Health launched a review of NHS rebates earlier this year under pressure from Donald Trump and the pharmaceutical industry. Ministers said they would take into account the 'concerns of the US president' that countries are unfairly keeping prices low relative to the high drug costs in the American health system. Under the trade agreement signed between the two nations earlier this year, the Government agreed to 'endeavour to improve the overall environment for pharmaceutical companies operating in the UK'. The failure to secure a deal ahead of the publication of the sector strategy follows months of wrangling. Under the current rebate scheme, known as VPAG, pharmaceutical companies have to hand at least 23pc of their revenue from sales of branded medicines back to the NHS. The scheme cut the drug bill by £3bn last year. However, pharmaceutical bosses have warned the scheme is preventing the launch of cutting-edge medicines in the UK. They have pressed for the UK to cut the rate of rebates into single digits, a level seen elsewhere in Europe. The life sciences strategy is one of several sector plans announced as part of Labour's industrial strategy. Others were published this week. A spokesman for the Government said: 'Economic growth is our number one priority and we're taking decisive action to unlock innovation and drive investment in the UK's world-class pharmaceutical sector. As part of this, we continue to work closely with industry on a rapid review of our voluntary scheme for medicines pricing. 'With our work and investment, we will make sure the next game changers in medicine are developed here in Britain, for the benefit of our health at home and abroad.'
Leader Live
an hour ago
- Leader Live
Weight loss jabs linked to potentially fatal side effects
Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have been fatal. Data from the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), shows that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines. The new weight management medication 'Tirzepatide' (brand name Mounjaro®) is shortly being made available to NHS patients to support weight loss. Access is prioritised for those with the greatest clinical need. You can find out more at: This includes: These cases are not confirmed as being caused by the medicines, but the person who reported them suspected they may be. Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: Nonetheless, Yellow Card Biobank project, launched by the MHRA and Genomics England, will see researchers examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by peoples genetic makeup. The MHRA is calling for people who are taking GLP-1 medicine who have been admitted to hospital due to acute pancreatitis to submit a report to its Yellow Card scheme. When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study. Patients will be asked to submit more information and a saliva sample which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes. GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss. 🧵Weight loss jab roll out 'positive for patients' but with implications for general practice that must be considered. Our Chair Kamila Hawthorne has featured widely in the national press and broadcast media responding to the phased roll-out of Mounjaro prescriptions by NHS… Chronic stress and poor sleep are major weight loss blockers. Stress increases cortisol, a hormone linked to fat retention, especially around the abdomen. Sleep deprivation increases ghrelin (hunger hormone) and decreases leptin (fullness hormone), making you more likely to overeat and less likely to move. You're also more impulsive and less motivated when sleep-deprived, making it harder to stick to your diet and exercise routine. As a solution, prioritise stress management techniques (like mindfulness or journaling), and aim for 7-9 hours of sleep per night. Medical issues such as PCOS, diabetes, hypothyroidism, or insulin resistance can all interfere with weight loss. Similarly, certain medications (like antidepressants or steroids) may cause weight gain or inhibit fat loss. If weight loss stalls despite doing everything right, consult your GP to rule out or address any underlying conditions. If you have a known medical condition, it's important to stay up to date with your routine reviews and inform your GP or specialist about any weight loss treatments you're using. Regular follow-up helps ensure your treatment plan remains safe and effective. More Mounjaro news... Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects. Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea. And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients. Dr Alison Cave, MHRA's chief safety officer, said: 'Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone. 'Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions – enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. 'To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. 'Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.' Professor Matt Brown, chief scientific officer of Genomics England, said: 'GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. 'We believe there is real potential to minimise these with many adverse reactions having a genetic cause. 'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'
